Top news of the week: 18.02.2021.
Companies And Industries
2021 Biopharma Update on the Novel Coronavirus: February 16
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for February 16, 2021.
Pfizer, Verily-backed Alzheimer's biotech Cortexyme hit by FDA partial hold over liver toxicity
As it looks for a new way to treat Alzheimer’s and clear a near 20-year backlog of failed R&D for the memory-wasting disease, big-name-backed biotech Cortexyme has hit a snag.
AI Generates Unprecedented Diversity of AAV Capsids
AI advances gene therapies by generating the functional diversity needed for AAVs to evade neutralization by the immune system.
On Streamlining Kick, GSK Divests Antibiotics Business to Sandoz for $500 Million
Under the terms of the deal, Sandoz is paying GSK $350 million at closing and additional milestones up to $150 million.
Turning Point Therapeutics is ‘Cycling’ Toward a Precise Cure for Cancer
The company's lead drug candidate, Reprotrectinib, is currently in Phase I/II clinical studies to target non-small cell lung cancer (NSCLC) in patients with a ROS1 or NTRK metastatic ...
Eyeing variants, Adagio starts phase 1 trial of COVID-19 antibody
Adagio Therapeutics has dosed the first subject with its anti-SARS-CoV-2 antibody. Administration of the candidate, which Adagio expects to be effective against coronavirus variants, ...
Amicus misses goal in Pompe phase 3 but still pushes for approval, showdown with Sanofi
A phase 3 clinical trial of Amicus Therapeutics’ late-onset Pompe disease prospect has missed its primary endpoint. Yet Amicus looked past the failure of AT-GAA to improve statistically on ...
Clinical Catch-Up: February 8-12
It was a busy week for clinical trial announcements and news. Here’s a look.